News & Views | Published:

Drug discovery

Chemical beauty contest

Nature volume 481, pages 455456 (26 January 2012) | Download Citation

Most drug candidates fail clinical trials, in many cases because the compounds have less than optimal physico-chemical properties. A new method for assessing the 'drug-likeness' of compounds might help to remedy the situation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & Nature Chem. 4, 90–98 (2012).

  2. 2.

    , , & Adv. Drug Delivery Rev. 23, 3–25 (1997).

  3. 3.

    , , , & J. Med. Chem. 46, 1250–1256 (2003).

  4. 4.

    et al. Bioorg. Med. Chem. Lett. 18, 4872–4875 (2008).

  5. 5.

    et al. Bioorg. Med. Chem. Lett. 21, 5673–5679 (2011).

  6. 6.

    & Nature Rev. Drug Discov. 6, 881–890 (2007).

  7. 7.

    & Nature Rev. Drug Discov. 10, 749–765 (2011).

  8. 8.

    Med. Chem. Commun. 2, 349–355 (2011).

  9. 9.

    et al. ACS Chem. Neurosci. 1, 435–449 (2010).

  10. 10.

    , & J. Med. Chem. 47, 4891–4896 (2004).

  11. 11.

  12. 12.

    , , & Angew. Chem. Int. Edn 38, 3743–3748 (1999).

  13. 13.

    Nature Chem. Biol. 7, 335–339 (2011).

Download references

Author information

Affiliations

  1. Paul Leeson is at the GlaxoSmithKline Medicines Research Centre, Stevenage SG1 2NY, UK.

    • Paul Leeson

Authors

  1. Search for Paul Leeson in:

Corresponding author

Correspondence to Paul Leeson.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/481455a

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing